Key result
Review weighs continuing versus stopping oral anticoagulation after successful catheter ablation for atrial fibrillation.
Why the study?
Oral anticoagulants reduce stroke and mortality in AF but confer major bleeding risk, while catheter ablation reduces stroke risk and AF burden. Recent trials and observational data have created debate about whether OAC can be routinely stopped after successful catheter ablation in patients at intermediate or low stroke risk.
Does cessation of oral anticoagulation increase the risk of thromboembolism or reduce major bleeding compared to continuation of oral anticoagulation in patients with atrial fibrillation at intermediate or low stroke risk after successful catheter ablation?
Does cessation of oral anticoagulation increase the risk of thromboembolism or reduce major bleeding compared to continuation of oral anticoagulation in patients with atrial fibrillation at intermediate or low stroke risk after successful catheter ablation?
This pro/contra review debates the clinical arguments and recent evidence regarding whether oral anticoagulation can be safely discontinued after successful catheter ablation of atrial fibrillation in patients at intermediate or low stroke risk.
Answers are grounded in this paper and cite their sources.
Anticoagulation decisions after successful AF ablation require individualized risk-benefit assessment; leaves open the need for dedicated RCTs to resolve equipoise.
The pillars of atrial fibrillation (AF) management include stroke prevention, patient-centred symptom directed decisions on rhythm or rate control, and the proactive management of comorbidities and lifestyle changes. These pillars are not in isolation; they are complementary to each other. While oral anticoagulants (OACs) are highly effective for reducing stroke and all-cause mortality in patients with AF, these drugs confer a risk of major bleeding, including intracranial bleeding. Evidence from clinical trials and observational data shows that early rhythm control, especially with catheter ablation, results in a reduction in stroke risk and/or the reduction in AF burden. The question arises therefore, whether in patients with intermediate or low stroke risk after successful catheter ablation, whether or not to continue or discontinue OAC. Recent randomized trials and observational data have created some debate about whether OAC can be routinely stopped after a successful catheter ablation procedure, without a higher risk of thromboembolism. In this pro/contra article, we will debate the arguments for and against the cessation of anti-coagulation after catheter ablation, in the context of recent evidence from clinical trials, observational data, and meta-analysis.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2026) conducted a review in Atrial fibrillation after catheter ablation. Oral anticoagulation continuation vs cessation after catheter ablation vs. Cessation or continuation of oral anticoagulation was evaluated. Oral anticoagulation continuation versus cessation after successful atrial fibrillation catheter ablation is debated in this pro/contra review, with no quantitative primary data reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: